Literature DB >> 1530893

Vasodilating actions of calcitonin gene-related peptide in normal man: comparison with atrial natriuretic peptide.

K Ando1, Y Ito, E Ogata, T Fujita.   

Abstract

To compare the vasodilator effect of calcitonin gene-related peptide (CGRP) with that of atrial natriuretic peptide (ANP), forearm blood flow (FBF) was measured by strain-gauge plethysmography during the continuous infusion of different doses of the peptides dissolved in 5% dextrose into the brachial artery in healthy subjects. Either CGRP or ANP increased FBF in a dose-dependent fashion. Although 100 ng/ml CGRP increased FBF from 3.27 +/- 0.41 to 10.70 +/- 1.77 ml/100 ml/min, the same dose of ANP increased FBF from 2.40 +/- 0.38 to 5.39 +/- 0.22 ml/100 ml/min, which was significantly lower than the increase in CGRP (p less than 0.01): Plasma concentration of peptides (on a molar basis) was positively correlated with FBF in CGRP (r = 0.820, p less than 0.01) or ANP (r = 0.722, p less than 0.01). However, the slope of the regression line between plasma level and FBF was significantly higher (p less than 0.01) in CGRP (12.88 +/- 0.99) than in ANP (2.10 +/- 0.27). Thus the vasodilator effect of CGRP was more potent than that of ANP. The present findings are compatible with functional involvement of CGRP in the regulation of forearm circulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530893     DOI: 10.1016/0002-8703(92)90754-j

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

Review 1.  Neuroendocrine changes in chronic cardiac failure.

Authors:  D P Nicholls; G N Onuoha; G McDowell; J S Elborn; M S Riley; A M Nugent; I C Steele; C Shaw; K D Buchanan
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

2.  Reproducibility of forearm vasodilator response to intra-arterial infusion of calcitonin gene-related peptide assessed by venous occlusion plethysmography.

Authors:  Floris H M Vanmolkot; Jan N J M de Hoon
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.